These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23422483)

  • 1. M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.
    Chaouche-Mazouni S; Copin MC; Lassalle P; Lebaili N; Cortot A; Scherpereel A
    In Vivo; 2013; 27(2):227-32. PubMed ID: 23422483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.
    Chaouche-Mazouni S; Scherpereel A; Zaamoum R; Mihalache A; Amir ZC; Lebaïli N; Delaire B; Gosset P
    Ann Diagn Pathol; 2015 Aug; 19(4):193-7. PubMed ID: 25935651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
    Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
    J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
    Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
    Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
    Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
    Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
    J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.
    Volta V; Ranzato E; Martinotti S; Gallo S; Russo MV; Mutti L; Biffo S; Burlando B
    PLoS One; 2013; 8(3):e58051. PubMed ID: 23526965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent.
    Jagirdar RM; Apostolidou E; Molyvdas PA; Gourgoulianis KI; Hatzoglou C; Zarogiannis SG
    Am J Physiol Lung Cell Mol Physiol; 2016 Mar; 310(6):L489-95. PubMed ID: 26773069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
    Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
    [No Abstract]   [Full Text] [Related]  

  • 14. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
    Reid G; Pel ME; Kirschner MB; Cheng YY; Mugridge N; Weiss J; Williams M; Wright C; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; Brahmbhatt H; MacDiarmid JA; van Zandwijk N
    Ann Oncol; 2013 Dec; 24(12):3128-35. PubMed ID: 24148817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment.
    Karatkevich D; Losmanova T; Zens P; Deng H; Dubey C; Zhang T; Casty C; Gao Y; Neppl C; Berezowska S; Wang W; Peng RW; Schmid RA; Dorn P; Marti TM
    Sci Rep; 2024 Aug; 14(1):18206. PubMed ID: 39107509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
    Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
    Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.
    Manente AG; Pinton G; Zonca S; Cilli M; Rinaldi M; Daga A; Nilsson S; Moro L
    Oncotarget; 2015 Sep; 6(28):25121-34. PubMed ID: 26208479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
    Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
    Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.
    Li Q; Wang W; Machino Y; Yamada T; Kita K; Oshima M; Sekido Y; Tsuchiya M; Suzuki Y; Nan-Ya K; Iida S; Nakamura K; Iwakiri S; Itoi K; Yano S
    Cancer Sci; 2015 Jan; 106(1):102-7. PubMed ID: 25421609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
    Hegedüs L; Okumus Ö; Mairinger F; Ploenes T; Reuter S; Schuler M; Welt A; Vega-Rubin-de-Celis S; Theegarten D; Bankfalvi A; Aigner C; Hegedüs B
    Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.